|
 The drug, Qulipta, which AbbVie will launch in early October, will
enter a crowded market for migraine prevention drugs such as Eli
Lilly's Emgality, Amgen Inc's Aimovig and Biohaven Pharmaceutical
Holding Co Ltd's Nurtec ODT.
Analysts expect the drug to bring in sales of over $640 million by
2025, according to Refinitiv data.
AbbVie acquired Qulipta in 2020 as part of its $63 billion deal for
Allergan, along with anti-wrinkle and chronic migraine treatment
Botox and acute migraine drug Ubrelvy.
Qulipta belongs to a class of drugs called calcitonin gene-related
peptide (CGRP) receptor antagonists, also called "gepants", which
act by blocking a pathway that seemingly plays a role in migraine
activation.
[to top of second column] |
 The Food and Drug
Administration's approval of Qulipta is
supported by data from a late-stage study, which
showed the drug caused a statistically
significant reduction in average monthly
headache days in patients compared to placebo.
Migraine, characterized by severe headache and
other symptoms such as light sensitivity and
nausea, affects about 39 million people in the
United States, AbbVie said.
(Reporting by Manojna Maddipatla in Bengaluru;
Editing by Krishna Chandra Eluri)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |
